Growth InvestmentsSlowing top line momentum coupled with lower margins due to ongoing growth investments, especially in marketing, would be taken negatively.
ProfitabilityThe intensified marketing efforts for Rx also came at a cost of slightly lower profitability in FY24.
Sales SlowdownGerman Rx sales showed a sequential slowdown, with only €6m incremental sales.